Maintenance Immunotherapy in #MOGAD#NeurologyMinute@AANmember
https://t.co/Pg0KFoDTxP
🎙️There is strong evidence that ≥12.5 mg/day (0.16 mg/kg/day paediatric) corticosteroids for 5 months from MOGAD onset reduces risk of relapse and permanent disability📉
#Neuroimmunology
Maintenance Immunotherapy in MOGAD: Early Steroid Benefit, Dose Thresholds, and Disability Risk - Part 2 of 3 (Non-steroidal maintenance therapies) #rituximab#ivig#steroidsparers#MOGAD
https://t.co/Gc7fR8r56U
Key Point 1 from the article Treatment of Multiple Sclerosis by Drs. Ellen M. Mowry, Darin T. Okuda, and Daniel Ontaneda from the April #MultipleSclerosis and Related Disorders issue, which is available to subscribers at https://t.co/mEtsb5LxTA. #NeuroTwitter#MedEd
Key Point 7 from the article Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease by Eoin P. Flanagan and Cheryl Hemingway from the April #MultipleSclerosis and Related Disorders issue, which is available to subscribers at https://t.co/SjuTSSJndV. #NeuroTwitter#MedEd
So exciting to see @mlevy18 present at #AANAM on satralizumab as the 1st proven treatment for attack-prevention in #MOGAD ➡️ A wonderful day for the #MOGAD community!
Nothing sharpens your own thinking quite like a room full of neurologists poking at it. Packed house, incisive questions, proper debate. Plenty to take home and consider. Thank you 🙏 #AANAM 2026 #MOGAD
Thank you to all contributors, pwMOGAD and especially 🙏 to Profs/Drs @darshi_r, Tomas Kalincik, Saif Huda, Russell Dale, @FabienneBrilot, @MiriForcadela and Chiara Rocchi. 🙌
Among adult patients with #MOGAD, discontinuation of oral immunosuppressants or rituximab was associated with a low 1-year relapse risk, especially after ≥1 year of treatment and ≥2 years since last relapse.
https://t.co/f1aj6CbYGC
The latest issue of Continuum is online!
MS and related disorders are obviously highly dynamic areas of our field. But there are a few features of this issue that stand out…